EA201490795A1 - 3,4-дизамещенное пиридиновое соединение, способы применения и содержащие его композиции - Google Patents

3,4-дизамещенное пиридиновое соединение, способы применения и содержащие его композиции

Info

Publication number
EA201490795A1
EA201490795A1 EA201490795A EA201490795A EA201490795A1 EA 201490795 A1 EA201490795 A1 EA 201490795A1 EA 201490795 A EA201490795 A EA 201490795A EA 201490795 A EA201490795 A EA 201490795A EA 201490795 A1 EA201490795 A1 EA 201490795A1
Authority
EA
Eurasian Patent Office
Prior art keywords
designed
cyanonaphthalen
pyridin
thio
containing compositions
Prior art date
Application number
EA201490795A
Other languages
English (en)
Other versions
EA026101B1 (ru
Inventor
Ли-Тайн Е
Барри Д. Кварт
Original Assignee
Ардеа Биосайнсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ардеа Биосайнсиз, Инк. filed Critical Ардеа Биосайнсиз, Инк.
Publication of EA201490795A1 publication Critical patent/EA201490795A1/ru
Publication of EA026101B1 publication Critical patent/EA026101B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

2-((3-(4-Цианонафталин-1-ил)пиридин-4-ил)тио)-2-метилпропановая кислота полезна для регулирования уровней мочевой кислоты в крови или сыворотке крови. В некоторых вариантах выполнения изобретения 2-((3-(4-цианонафталин-1-ил)пиридин-4-ил)тио)-2-метилпропановую кислоту применяют при лечении или профилактике расстройств, связанных с аномальными уровнями мочевой кислоты. В некоторых вариантах выполнения изобретения 2-((3-(4-цианонафталин-1-ил)пиридин-4-ил)тио)-2-метилпропановую кислоту применяют для снижения сывороточных уровней мочевой кислоты в организме человека. В настоящем изобретении также описаны композиции, содержащие 2-((3-(4-цианонафталин-1-ил)пиридин-4-ил)тио)-2-метилпропановую кислоту, и их применение для регулирования уровней мочевой кислоты в крови или сыворотке крови.
EA201490795A 2011-11-03 2012-11-02 Применение 3,4-дизамещенного пиридинового соединения для снижения уровня мочевой кислоты в сыворотке крови EA026101B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555450P 2011-11-03 2011-11-03
US201261616363P 2012-03-27 2012-03-27
PCT/US2012/063415 WO2013067425A1 (en) 2011-11-03 2012-11-02 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same

Publications (2)

Publication Number Publication Date
EA201490795A1 true EA201490795A1 (ru) 2014-09-30
EA026101B1 EA026101B1 (ru) 2017-03-31

Family

ID=47178362

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490795A EA026101B1 (ru) 2011-11-03 2012-11-02 Применение 3,4-дизамещенного пиридинового соединения для снижения уровня мочевой кислоты в сыворотке крови

Country Status (22)

Country Link
US (2) US10047050B2 (ru)
EP (2) EP3501520A1 (ru)
JP (1) JP6025853B2 (ru)
KR (1) KR101988066B1 (ru)
CN (2) CN106963761A (ru)
AU (1) AU2012332154B2 (ru)
BR (1) BR112014010495A2 (ru)
CA (1) CA2852490A1 (ru)
DK (1) DK2776028T3 (ru)
EA (1) EA026101B1 (ru)
ES (1) ES2704233T3 (ru)
HK (1) HK1198929A1 (ru)
HU (1) HUE040625T2 (ru)
IL (1) IL232105A (ru)
MX (1) MX352904B (ru)
MY (1) MY180138A (ru)
PH (1) PH12014500997B1 (ru)
PL (1) PL2776028T3 (ru)
SG (1) SG11201402016PA (ru)
UA (1) UA114304C2 (ru)
WO (1) WO2013067425A1 (ru)
ZA (1) ZA201402795B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
EP3501520A1 (en) * 2011-11-03 2019-06-26 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
CN104311452B (zh) * 2014-09-27 2016-01-06 张远强 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途
CN104292124B (zh) * 2014-09-27 2016-01-20 张远强 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途
CN108026043A (zh) * 2015-08-14 2018-05-11 广东东阳光药业有限公司 一种萘环化合物的晶型
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1
CN105884807A (zh) * 2016-04-26 2016-08-24 昆药集团股份有限公司 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法
CN106117130A (zh) * 2016-06-28 2016-11-16 昆药集团股份有限公司 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物
CN114315715B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与应用
JP7449837B2 (ja) 2020-10-09 2024-03-14 フジモリ産業株式会社 建物用煙突の継手構造

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6054310B2 (ja) 1979-02-21 1985-11-29 三井東圧化学株式会社 ピリダジン誘導体と農園芸用殺菌剤
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5051442A (en) 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
DE69122084T2 (de) 1990-11-30 1997-04-03 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
CA2105617A1 (en) 1992-09-10 1994-03-11 Yoshikazu Iwasawa Substituted acetamide derivatives
US5344651A (en) 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
WO2001091796A2 (en) * 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
GB0108339D0 (en) 2001-04-03 2001-05-23 Syngenta Participations Ag Organics compounds
JP3824899B2 (ja) * 2001-09-21 2006-09-20 株式会社ヒューマンセルシステムズ 腎臓及び胎盤型尿酸トランスポーターとその遺伝子
EA015846B1 (ru) 2004-08-25 2011-12-30 Ардеа Байосайенсиз, Инк. 2-[5-бром-4-(4-циклопропилнафталин-1-ил)-4н-[1,2,4]триазол-3-илсульфанил]уксусная кислота и ее метиловый эфир
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070099970A1 (en) 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
JP2009530399A (ja) 2006-03-22 2009-08-27 シンデクサ ファーマシューティカルズ コーポレーション Ｅｒストレスに関連する疾病の治療のための化合物及び方法
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
NZ601786A (en) 2007-11-27 2014-02-28 Ardea Biosciences Inc Novel compounds and compositions and methods of use
RU2522458C2 (ru) * 2008-04-30 2014-07-10 Веллстат Терапьютикс Корпорейшн Тетразольные соединения для снижения концентрации мочевой кислоты
WO2010028189A2 (en) 2008-09-04 2010-03-11 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010135536A2 (en) 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Methods of modulating uric acid levels
EP2432774A4 (en) 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
WO2011044140A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
BR112012016795A2 (pt) 2010-01-08 2020-09-01 Ardea Biosciences Inc. formas polimórficas, cristalinas e de mesofase de 2-(5- bromo -4-(4-ciclopropilnaftalen-1-il)-4h-1,2,34-triazol-3iltio) acetato de sódio e seus usos
CA2794798C (en) * 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
PL2582683T3 (pl) * 2010-06-15 2018-08-31 Ardea Biosciences, Inc. Leczenie dny moczanowej i hiperurykemii
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
WO2011159840A2 (en) 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
EP3501520A1 (en) 2011-11-03 2019-06-26 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1

Also Published As

Publication number Publication date
CN106963761A (zh) 2017-07-21
AU2012332154B2 (en) 2016-11-17
JP2014532726A (ja) 2014-12-08
JP6025853B2 (ja) 2016-11-16
IL232105A (en) 2017-05-29
MX2014005343A (es) 2014-09-08
ES2704233T3 (es) 2019-03-15
MY180138A (en) 2020-11-23
EA026101B1 (ru) 2017-03-31
WO2013067425A1 (en) 2013-05-10
HUE040625T2 (hu) 2019-03-28
US10047050B2 (en) 2018-08-14
KR101988066B1 (ko) 2019-09-27
NZ623857A (en) 2016-08-26
CN104023723A (zh) 2014-09-03
EP2776028B1 (en) 2018-10-17
PL2776028T3 (pl) 2019-03-29
BR112014010495A2 (pt) 2017-04-25
EP2776028A1 (en) 2014-09-17
UA114304C2 (uk) 2017-05-25
US20140256748A1 (en) 2014-09-11
CA2852490A1 (en) 2013-05-10
PH12014500997A1 (en) 2014-08-04
MX352904B (es) 2017-12-13
IL232105A0 (en) 2014-05-28
CN104023723B (zh) 2017-05-31
DK2776028T3 (en) 2019-02-04
PH12014500997B1 (en) 2014-08-04
EP3501520A1 (en) 2019-06-26
SG11201402016PA (en) 2014-05-29
US10570095B2 (en) 2020-02-25
KR20140095078A (ko) 2014-07-31
HK1198929A1 (en) 2015-06-19
US20190135756A1 (en) 2019-05-09
ZA201402795B (en) 2019-09-25
AU2012332154A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
EA201490795A1 (ru) 3,4-дизамещенное пиридиновое соединение, способы применения и содержащие его композиции
EA201100441A1 (ru) Соединения для коррекции уровня мочевой кислоты и способы их применения
UA107115C2 (uk) Тіоацетатні похідіні піридину, композиція на їх основі та їх застосування
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
EA201170349A1 (ru) Модуляторы mif
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
MY180626A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EA200971053A1 (ru) Способы лечения кожных язв
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
BR112013027034A8 (pt) "compostos para o tratamento de transtornos neuropsiquiátricos."
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
BR112015012538A2 (pt) anticorpos anti-vegf e seus usos
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
BR112014011780A2 (pt) dispositivo para filtração, secagem e armazenamento de sólidos a partir de uma suspensão
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
BR112014010729A2 (pt) métodos para tratamento de ataques de gota